706 related articles for article (PubMed ID: 17592264)
41. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R
Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744
[TBL] [Abstract][Full Text] [Related]
42. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma.
Kendall BS; Ronnett BM; Isacson C; Cho KR; Hedrick L; Diener-West M; Kurman RJ
Am J Surg Pathol; 1998 Aug; 22(8):1012-9. PubMed ID: 9706982
[TBL] [Abstract][Full Text] [Related]
43. Endometrial brush biopsy. An accurate outpatient method of detecting endometrial malignancy.
Wu HH; Casto BD; Elsheikh TM
J Reprod Med; 2003 Jan; 48(1):41-5. PubMed ID: 12611094
[TBL] [Abstract][Full Text] [Related]
44. Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report.
Corrado G; Baiocco E; Carosi M; Vizza E
Fertil Steril; 2008 Nov; 90(5):2006.e5-8. PubMed ID: 18692828
[TBL] [Abstract][Full Text] [Related]
45. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.
Kresowik J; Ryan GL; Van Voorhis BJ
Obstet Gynecol; 2008 Feb; 111(2 Pt 2):547-9. PubMed ID: 18239018
[TBL] [Abstract][Full Text] [Related]
46. [Endometrial adenocarcinoma in women 40 years old or younger by treatment with progestins: report of 6 cases and review of the literatures].
Wang HY; Shen L; Sun Z
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):237-41. PubMed ID: 16759457
[TBL] [Abstract][Full Text] [Related]
47. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.
Gadducci A; Spirito N; Baroni E; Tana R; Genazzani AR
Gynecol Endocrinol; 2009 Oct; 25(10):683-91. PubMed ID: 19562604
[TBL] [Abstract][Full Text] [Related]
48. Determining the inter- and intraobserver reproducibility of the diagnosis of endometrial hyperplasia subgroups and well-differentiated endometrioid carcinoma in endometrial curettage specimens.
Izadi-Mood N; Khaniki M; Irvanloo G; Ahmadi SA; Hayeri H; Meysamie A
Arch Iran Med; 2009 Jul; 12(4):377-82. PubMed ID: 19566355
[TBL] [Abstract][Full Text] [Related]
49. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
Haoula ZJ; Walker KF; Powell MC
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):176-9. PubMed ID: 21741152
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.
Baker J; Obermair A; Gebski V; Janda M
Gynecol Oncol; 2012 Apr; 125(1):263-70. PubMed ID: 22196499
[TBL] [Abstract][Full Text] [Related]
51. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
[TBL] [Abstract][Full Text] [Related]
52. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.
Zaino RJ; Brady WE; Todd W; Leslie K; Fischer EG; Horowitz NS; Mannel RS; Walker JL; Ivanovic M; Duska LR
Int J Gynecol Pathol; 2014 Nov; 33(6):543-53. PubMed ID: 25272292
[TBL] [Abstract][Full Text] [Related]
53. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives.
Shen ZQ; Zhu HT; Lin JF
Obstet Gynecol; 2008 Aug; 112(2 Pt 2):465-7. PubMed ID: 18669766
[TBL] [Abstract][Full Text] [Related]
54. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
[TBL] [Abstract][Full Text] [Related]
55. Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view.
Ricciardi E; Maniglio P; Frega A; Marci R; Caserta D; Moscarini M
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1934-7. PubMed ID: 23242719
[TBL] [Abstract][Full Text] [Related]
56. Endoplasmic reticulum stress in complex atypical hyperplasia as a possible predictor of occult carcinoma and progestin response.
Tierney KE; Ji L; Dralla SS; Yoo E; Yessaian A; Pham HQ; Roman L; Sposto R; Mhawech-Fauceglia P; Lin YG
Gynecol Oncol; 2016 Dec; 143(3):650-654. PubMed ID: 27771165
[TBL] [Abstract][Full Text] [Related]
57. Atypical mucinous glandular proliferations in endometrial samplings: follow-up and other clinicopathological findings in 41 cases.
Rawish KR; Desouki MM; Fadare O
Hum Pathol; 2017 May; 63():53-62. PubMed ID: 28232161
[TBL] [Abstract][Full Text] [Related]
58. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data.
Agorastos T; Bontis J; Vakiani A; Vavilis D; Constantinidis T
Gynecol Oncol; 1997 Apr; 65(1):102-14. PubMed ID: 9103399
[TBL] [Abstract][Full Text] [Related]
59. Clinicopathological and immunohistochemical characterization of papillary proliferation of the endometrium: A single institutional experience.
Park CK; Yoon G; Cho YA; Kim HS
Oncotarget; 2016 Jun; 7(26):39197-39206. PubMed ID: 27322430
[TBL] [Abstract][Full Text] [Related]
60. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review.
Ramirez PT; Frumovitz M; Bodurka DC; Sun CC; Levenback C
Gynecol Oncol; 2004 Oct; 95(1):133-8. PubMed ID: 15385122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]